Medicare Benefits Schedule - Item 73329

A nucleic acid-based multi-gene panel test of tumour tissue from a patient with cholangiocarcinoma requested by, or on behalf of, a specialist or consultant physician, if the test is to:

(a)      detect at least IDH1 variant status, and

(b)      detect the fusion or rearrangement status of at least FGFR2; and

(c)      determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme

including a service described in item 73319.

Applicable once per lifetime.

Fee: $800.00 Benefit: 75% = $600.00 85% = $695.50

• Previous - Item 73327
• Next - Item 73332